Key result
Proteinase-activated receptors emerge as novel therapeutic targets for treating inflammation.
Why the study?
Proteinase-activated receptors (PARs) play distinct roles in inflammatory processes, but their precise functions and therapeutic potential require clarification.
Proteinase-activated receptors (PARs) emerge as potential novel therapeutic targets for the treatment of inflammation.
No immediate change to anti-inflammatory practice warranted; leaves open PARs as targets for prospective validation.
Inflammation, which constitutes the body's response to injury, is characterized by a series of events where several different cell types are playing distinct roles. Proteinase‐activated receptors (PARs) are expressed in all the cell types that are involved in inflammatory processes. The expression of PARs is up‐regulated during inflammatory processes. Activation of PARs can lead to inflammation or, in some circumstances, can be protective against uncontrolled inflammatory reaction. Most recently, studies have shown that inflammatory responses were altered in PAR‐deficient mice. Thus, a crucial role for PARs seems to emerge from the most recent literature and presents PARs as novel and interesting therapeutic targets for the treatment of inflammation. Drug Dev. Res. 59:375–381, 2003.
No takes yet. Share an insight, caveat, or question.
Nathalie Vergnolle (2003) conducted a review in Inflammation. Proteinase-activated receptors (PARs) targeting was evaluated. Proteinase-activated receptors (PARs) play a crucial role in the inflammatory response and emerge as novel therapeutic targets for the treatment of inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: